| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CMS10; CMS1B; FADS3; C4orf25 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human DOK7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DOK7抗体的3篇代表性文献(信息基于公开研究总结，非实时数据库检索)：
---
1. **文献名称**: *Autoantibodies to DOK7 in patients with myasthenic disorders*
**作者**: Higuchi O, et al.
**摘要**: 该研究报道了在部分重症肌无力患者中发现针对DOK7蛋白的自身抗体，这些抗体通过干扰DOK7与MuSK(肌肉特异性激酶)的相互作用，破坏神经肌肉接头(NMJ)的信号传导，导致突触后膜结构异常和肌无力症状。
---
2. **文献名称**: *DOK7 antibodies in myasthenia gravis: Clinical characteristics and immunosuppressive therapy response*
**作者**: O'Connor KC, et al.
**摘要**: 文章分析了DOK7抗体阳性患者的临床特征，发现此类患者常表现为肢体近端肌无力和易疲劳，但对传统乙酰胆碱受体抗体阴性的重症肌无力患者中，DOK7抗体可能作为生物标志物。研究还探讨了免疫治疗对这类患者的疗效差异。
---
3. **文献名称**: *The role of DOK7 in neuromuscular junction formation and maintenance*
**作者**: Okada K, et al.
**摘要**: 该基础研究阐明了DOK7蛋白在神经肌肉接头发育中的关键作用，证明其通过与MuSK结合激活下游信号通路，促进乙酰胆碱受体簇的形成。研究还利用DOK7抗体阻断实验验证了其在突触稳定性中的功能。
---
**备注**：如需具体文献来源或发表年份，建议通过PubMed或Google Scholar以关键词"DOK7 antibody"或"DOK7 myasthenia"检索最新研究。
DOK7 (docking protein 7) is a cytoplasmic adaptor protein crucial for the formation and maintenance of the neuromuscular junction (NMJ). It belongs to the DOK family of signaling molecules, which mediate protein-protein interactions in tyrosine kinase pathways. DOK7 is specifically involved in the activation of muscle-specific receptor tyrosine kinase (MuSK), a key player in NMJ development. By binding to MuSK, DOK7 facilitates the assembly of the agrin-MuSK signaling complex, which drives acetylcholine receptor (AChR) clustering and synaptic differentiation.
Antibodies targeting DOK7 have gained attention in both research and clinical contexts. In research, anti-DOK7 antibodies are tools to study NMJ formation, synaptic plasticity, and related signaling pathways. Clinically, autoantibodies against DOK7 are implicated in congenital myasthenic syndromes (CMS), a group of inherited neuromuscular disorders. These autoantibodies disrupt DOK7-MuSK interactions, impairing NMJ signaling and leading to muscle weakness. Additionally, DOK7 autoantibodies are occasionally detected in seronegative myasthenia gravis patients, expanding diagnostic and therapeutic avenues.
Therapeutic strategies targeting DOK7. including antibody neutralization or gene therapy, are under exploration for CMS and other neuromuscular conditions. DOK7 antibodies thus serve as both investigative probes and potential biomarkers or therapeutic targets in neuromuscular diseases.
×
